Finance

Lists
Outlook: 81.5% bullish·0.0% bearish
Go to analysis
LILY34:BVMF
Eli Lilly And Company BDR
R$260.29
+0.30%
(+0.78) 1D
Nov 4, 1:50:51 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for LILY34...
Open
R$263.00
High
R$263.88
Low
R$255.53
Mkt. cap
1.34T
Avg. vol.
48.37K
Volume
19.72K
52-wk high
R$263.88
52-wk low
R$141.70
Shares outstanding
940.75M
No. of employees
50K
Open
R$263.00
High
R$263.88
Low
R$255.53
Mkt. cap
1.34T
Avg. vol.
48.37K
Volume
19.72K
52-wk high
R$263.88
52-wk low
R$141.70
Shares outstanding
940.75M
No. of employees
50K
News stories
From web sources and news partners
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEODavid A. Ricks
Employees50K
Founded1876
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Industry-
Websitelilly.com
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$7.48 / $6.35
+17.88%beat
Revenue / Est. (USD)
24.40B / 22.62B
+7.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
19.29B
19.80B
22.97B
24.40B
Cost of goods sold
3.37B
3.58B
3.27B
3.93B
Cost of revenue
3.37B
3.58B
3.27B
3.93B
Research and development expenses
3.80B
3.51B
3.82B
4.25B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.46B
2.93B
3.43B
3.12B
Operating expense
7.26B
6.44B
7.25B
7.37B
Total operating expenses
10.63B
10.02B
10.52B
11.30B
Operating income
8.66B
9.78B
12.46B
13.09B
Other non operating income
181.20M
170.00M
561.00M
13.00M
EBT including unusual items
8.27B
8.85B
9.25B
8.41B
EBT excluding unusual items
8.89B
9.71B
12.73B
12.89B
Income tax expense
1.63B
1.45B
2.15B
1.96B
Effective tax rate
19.70%
16.43%
23.27%
23.26%
Other operating expenses
-
-
-
-
Net income
6.64B
7.40B
7.10B
6.45B
Net profit margin
34.41%
37.36%
30.88%
26.44%
Earnings per share
7.54
8.55
8.38
7.48
Interest and investment income
672.40M
-
-
-
Interest expense
-153.30M
-332.00M
-345.00M
-378.00M
Net interest expenses
519.10M
-332.00M
-345.00M
-378.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
9.25B
10.29B
12.99B
13.64B
Gain or loss from assets sale
-180.00M
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps